Early Reduction of FeNO on Anti‐IL5 Biologics Is Associated With Clinical Remission of Severe Asthma

IF 12.6 1区医学 Q1 ALLERGY

Allergy Pub Date : 2024-12-14 DOI:10.1111/all.16425

Marianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, Anna von Bülow, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen Bertelsen, Niels Steen Krogh, Ole Hilberg, Charlotte Suppli Ulrik, Celeste Porsbjerg

{"title":"Early Reduction of FeNO on Anti‐IL5 Biologics Is Associated With Clinical Remission of Severe Asthma","authors":"Marianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, Anna von Bülow, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen Bertelsen, Niels Steen Krogh, Ole Hilberg, Charlotte Suppli Ulrik, Celeste Porsbjerg","doi":"10.1111/all.16425","DOIUrl":null,"url":null,"abstract":"BackgroundIn patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes.MethodsWe used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease.ResultsWe identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function.ConclusionsFeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"14 1","pages":""},"PeriodicalIF":12.6000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/all.16425","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

BackgroundIn patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes.MethodsWe used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease.ResultsWe identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function.ConclusionsFeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.